From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?

Whether smokers respond to anti-cancer drugs differently than non-smokers remains controversial. The objective of this study is to explore whether the better response of the smokers is specific to therapy of anti-PD-1/PD-L1, anti-checkpoint inhibitor, individual drugs on the cell surface, or lung ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lishi, Liu, Fengxia, Li, Jing, Ma, Li, Feng, Helin, Liu, Qingyi, Cho, William C., Chen, Haiyong, Chen, Hong, Guo, Hua, Li, Zhujun, Howard, Scott C., Li, Minghui, Shan, Baoen, Gu, Weikuan, Ji, Jiafu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471889/
https://www.ncbi.nlm.nih.gov/pubmed/34575691
http://dx.doi.org/10.3390/jpm11090914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471889/
https://www.ncbi.nlm.nih.gov/pubmed/34575691
http://dx.doi.org/10.3390/jpm11090914

Ejemplares similares